Tissue microarrays in drug discovery (original) (raw)

• Goldstine, J., Seligson, D. B., Beizai, P., Miyata, H. & Vinters, H. V. Tissue microarrays in the study of non-neoplastic disease of the nervous system. J. Neuropathol. Exp. Neurol. 61, 653–662 (2002).
  PubMed Google Scholar
• Bubendorf, L. et al. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res. 59, 803–806 (1999).
  CAS PubMed Google Scholar
• Kononen, J. et al. Tissue microarrays for high-throughput molecular profiling of hundreds of specimens. Nature Med. 4, 844–847 (1998). Initial publication of the TMA technology.
  CAS PubMed Google Scholar
• Fejzo, M. S. & Slamon, D. J. Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. Am. J. Pathol. 159, 1645–1650 (2001). Describes TMAs from frozen tissue samples.
  CAS Google Scholar
• Simon, R. & Sauter, G. Tissue microarrays for miniaturized high-throughput molecular profiling of tumors. Exp. Hematol. 30, 1365–1372 (2002).
  CAS PubMed Google Scholar
• Gancberg, D. et al. Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma. J. Clin. Pathol. 55, 315–317 (2002).
  CAS PubMed PubMed Central Google Scholar
• Camp, R. L., Charette, L. A. & Rimm, D. L. Validation of tissue microarray technology in breast carcinoma. Lab. Invest. 80, 1943–1949 (2000). An early TMA-validation study.
  CAS PubMed Google Scholar
• Rimm, D. L. et al. Tissue microarray: a new technology for amplification of tissue resources. Cancer J. 7, 24–31 (2001).
  CAS PubMed Google Scholar
• Gancberg, D. et al. Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing. Breast Cancer Res. Treat. 74, 113–120 (2002).
  CAS PubMed Google Scholar
• Ginestier, C. et al. Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am. J. Pathol. 161, 1223–1233 (2002).
  CAS PubMed PubMed Central Google Scholar
• Torhorst, J. et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am. J. Pathol. 159, 2249–2256 (2001).
  CAS PubMed PubMed Central Google Scholar
• Hendriks, Y. et al. Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am. J. Pathol. 162, 469–477 (2003).
  CAS PubMed PubMed Central Google Scholar
• Fernebro, E., Dictor, M., Bendahl, P. O., Ferno, M. & Nilbert, M. Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch. Pathol. Lab. Med. 126, 702–705 (2002).
  PubMed Google Scholar
• Mucci, N. R., Akdas, G., Manely, S. & Rubin, M. A. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum. Pathol. 31, 406–414 (2000).
  CAS PubMed Google Scholar
• Rubin, M. A., Dunn, R., Strawderman, M. & Pienta, K. J. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am. J. Surg. Pathol. 26, 312–319 (2002). Illustrates that four punches per tissue sample provide optimal representativity.
  PubMed Google Scholar
• Merseburger, A. S. et al. Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. Oncol. Rep. 10, 223–228 (2003).
  CAS PubMed Google Scholar
• Gulmann, C., Butler, D., Kay, E., Grace, A. & Leader, M. Biopsy of a biopsy: validation of immunoprofiling in gastric cancer biopsy tissue microarrays. Histopathology 42, 70–76 (2003).
  CAS PubMed Google Scholar
• Moch, H. et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am. J. Pathol. 154, 981–986 (1999).
  CAS PubMed PubMed Central Google Scholar
• Nocito, A. et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J. Pathol. 194, 349–357 (2001).
  CAS PubMed Google Scholar
• Sallinen, S. L. et al. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res. 60, 6617–6622 (2000).
  CAS PubMed Google Scholar
• Engellau, J. et al. Tissue microarray technique in soft tissue sarcoma: immunohistochemical Ki-67 expression in malignant fibrous histiocytoma. Appl. Immunohistochem. Mol. Morphol. 9, 358–363 (2001).
  CAS PubMed Google Scholar
• Hoos, A. et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am. J. Pathol. 158, 1245–1251 (2001).
  CAS PubMed PubMed Central Google Scholar
• Rassidakis, G. Z. et al. Apoptotic rate in peripheral T-cell lymphomas. A study using a tissue microarray with validation on full tissue sections. Am. J. Clin. Pathol. 118, 328–334 (2002).
  PubMed Google Scholar
• Garcia, J. F. et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 101, 681–689 (2003). Reports TMA of Hodgkin's lymphoma samples.
  CAS PubMed Google Scholar
• Hedvat, C. V. et al. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum. Pathol. 33, 968–974 (2002). Describes TMA of Hodgkin's lymphoma samples.
  PubMed Google Scholar
• Tzankov, A. et al. High-throughput tissue microarray analysis of G1-cyclin alterations in classical Hodgkin's lymphoma indicates overexpression of cyclin E1. J. Pathol. 199, 201–207 (2003). An analysis of TMA of Hodgkin's lymphoma samples.
  CAS PubMed Google Scholar
• Torhorst, J. et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am. J. Pathol. 159, 2249–2256 (2001). Reports TMA evaluation of known prognostic factors (ER,PR) in breast cancer.
  CAS PubMed PubMed Central Google Scholar
• Barlund, M. et al. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J. Natl Cancer Inst. 92, 1252–1259 (2000). This study combines cDNA and TMA technologies.
  CAS PubMed Google Scholar
• Hoos, A. et al. High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. Cancer 92, 869–874 (2001).
  CAS PubMed Google Scholar
• Hoos, A. et al. Clinical significance of molecular expression profiles of Hurthle cell tumors of the thyroid gland analyzed via tissue microarrays. Am. J. Pathol. 160, 175–183 (2002).
  CAS PubMed PubMed Central Google Scholar
• Bubendorf, L. et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J. Natl Cancer Inst. 91, 1758–1764 (1999). Describes a combination of cDNA and TMA technologies.
  CAS PubMed Google Scholar
• Dhanasekaran, S. M. et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822–826 (2001).
  CAS PubMed Google Scholar
• Porkka, K., Saramaki, O., Tanner, M. & Visakorpi, T. Amplification and overexpression of Elongin C gene discovered in prostate cancer by cDNA microarrays. Lab. Invest. 82, 629–637 (2002).
  CAS PubMed Google Scholar
• Mousses, S. et al. Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res. 62, 1256–1260 (2002).
  CAS PubMed Google Scholar
• Xin, W., Rhodes, D. R., Ingold, C., Chinnaiyan, A. M. & Rubin, M. A. Dysregulation of the annexin family protein family is associated with prostate cancer progression. Am. J. Pathol. 162, 255–261 (2003).
  CAS PubMed PubMed Central Google Scholar
• Otsuka, M. et al. Differential expression of the L-plastin gene in human colorectal cancer progression and metastasis. Biochem. Biophys. Res. Commun. 289, 876–881 (2001).
  CAS PubMed Google Scholar
• Nielsen, T. O. et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 359, 1301–1307 (2002).
  CAS PubMed Google Scholar
• Allander, S. V. et al. Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am. J. Pathol. 161, 1587–1595 (2002).
  CAS PubMed PubMed Central Google Scholar
• Wasenius, V. M. et al. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin. Cancer Res. 9, 68–75 (2003).
  CAS PubMed Google Scholar
• Oka, T. et al. Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/ leukemias: combination analysis with cDNA expression array and tissue microarray. Am. J. Pathol. 159, 1495–1505 (2001).
  CAS PubMed PubMed Central Google Scholar
• Heiskanen, M. et al. CGH, cDNA and tissue microarray analyses implicate FGFR2 amplification in a small subset of breast tumors. Anal. Cell. Pathol. 22, 229–234 (2001).
  CAS PubMed PubMed Central Google Scholar
• Hyman, E. et al. Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res. 62, 6240–6245 (2002). CGH on cDNA microarrays.
  CAS PubMed Google Scholar
• Richter, J. et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am. J. Pathol. 157, 787–794 (2000). Describes an example of a prognosis TMA.
  CAS PubMed PubMed Central Google Scholar
• Simon, R. et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res. 61, 4514–4519 (2001).
  CAS PubMed Google Scholar
• Simon, R. et al. Amplification pattern of 12q13–q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene 21, 2476–2483 (2002). Amplicon mapping using different TMAs.
  CAS PubMed Google Scholar
• Kocher, T. et al. Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. Int. J. Cancer 100, 702–705 (2002).
  CAS PubMed Google Scholar
• Park, S. Y., Kim, H. S., Hong, E. K. & Kim, W. H. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum. Pathol. 33, 1078–1085 (2002).
  CAS PubMed Google Scholar
• Saramaki, O. et al. Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer. Am. J. Pathol. 159, 2089–2094 (2001).
  CAS PubMed PubMed Central Google Scholar
• Skacel, M. et al. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray. Hum. Pathol. 32, 1392–1397 (2001).
  CAS PubMed Google Scholar
• Rubin, M. A. et al. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum. Pathol. 32, 690–697 (2001).
  CAS PubMed Google Scholar
• Fuller, C. E., Wang, H., Zhang, W., Fuller, G. N. & Perry, A. High-throughput molecular profiling of high-grade astrocytomas: the utility of fluorescence in situ hybridization on tissue microarrays (TMA-FISH). J. Neuropathol. Exp. Neurol. 61, 1078–1084 (2002).
  CAS PubMed Google Scholar
• Ristimaki, A. et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 62, 632–635 (2002).
  CAS PubMed Google Scholar
• Miettinen, H. E. et al. High topoisomerase II α expression associates with high proliferation rate and and poor prognosis in oligodendrogliomas. Neuropathol. Appl. Neurobiol. 26, 504–512 (2000).
  CAS PubMed Google Scholar
• Wang, Y. et al. Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer 95, 2346–2352 (2002).
  CAS PubMed Google Scholar
• Simon, R. et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J. Natl Cancer Inst. 93, 1141–1146 (2001). This paper provides an example of a metastasis TMA.
  CAS PubMed Google Scholar
• Maloney, D. G. et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90, 2188–2195 (1997).
  CAS PubMed Google Scholar
• Rao, J., Seligson, D. & Hemstreet, G. P. Protein expression analysis using quantitative fluorescence image analysis on tissue microarray slides. Biotechniques 32, 924–926, 928–930, 932 (2002).
  CAS PubMed Google Scholar
• Camp, R. L., Chung, G. G. & Rimm, D. L. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nature Med. 8, 1323–1327 (2002). Describes an automated TMA analysis using fluorescent dyes.
  CAS PubMed Google Scholar
• Haedicke, W., Popper, H. H., Buck, C. R. & Zatloukal, K. Automated evaluation and normalization of immunohistochemistry on tissue microarrays with a DNA microarray scanner. Biotechniques 35, 164–168 (2003). Report of an automated TMA analysis.
  CAS PubMed Google Scholar
• Liu, C. L. et al. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am. J. Pathol. 161, 1557–1565 (2002).
  CAS PubMed PubMed Central Google Scholar
• Berman, J. J., Edgerton, M. E. & Friedman, B. A. The tissue microarray data exchange specification: A community-based, open source tool for sharing tissue microarray data. BMC Med. Inform. Decis. Mak. 3, 5 (2003).
  PubMed PubMed Central Google Scholar
• Schraml, P. et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin. Cancer Res. 5, 1966–1975 (1999). Provides an example of a multitumour TMA.
  CAS PubMed Google Scholar
• Sauer, T., Wiedswang, G., Boudjema, G., Christensen, H. & Karesen, R. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice? APMIS 111, 444–450 (2003).
  CAS PubMed Google Scholar
• Zhang, D., Salto-Tellez, M., Do, E., Putti, T. C. & Koay, E. S. Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. Hum. Pathol. 34, 362–368 (2003).
  CAS PubMed Google Scholar
• Latta, E. K., Tjan, S., Parkes, R. K. & O'Malley, F. P. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod. Pathol. 15, 1318–1325 (2002).
  CAS PubMed Google Scholar
• Bozzetti, C. et al. HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. Ann. Oncol. 13, 1398–1403 (2002).
  CAS PubMed Google Scholar
• Tsuda, H. et al. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer 92, 2965–2974 (2001).
  CAS PubMed Google Scholar
• Riou, G. et al. c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients. Int. J. Cancer 95, 266–270 (2001).
  CAS PubMed Google Scholar
• Chen, Y., Dong, J. & Li, C. Amplification and overexpression of c-erbB2 in human breast cancer. Zhonghua Zhong Liu Za Zhi 17, 16–19 (1995).
  CAS PubMed Google Scholar
• Hubbard, A. L., Doris, C. P., Thompson, A. M., Chetty, U. & Anderson, T. J. Critical determination of the frequency of c-erbB-2 amplification in breast cancer. Br. J. Cancer 70, 434–439 (1994).
  CAS PubMed PubMed Central Google Scholar
• Pechoux, C., Chardonnet, Y. & Noel, P. Immunohistochemical studies on c-erbB-2 oncoprotein expression in paraffin embedded tissues in invasive and non-invasive human breast lesions. Anticancer Res. 14, 1343–1360 (1994).
  CAS PubMed Google Scholar
• Bermont, L., Algros, M. P., Baron, M. H. & Adessi, G. L. Relevance of p185 HER-2/neu oncoprotein quantification in human primary breast carcinoma. Breast Cancer Res. Treat. 63, 163–169 (2000).
  CAS PubMed Google Scholar
• Knyazev, P. G., Imyanitov, E. N., Chernitca, O. I., Nikiforova, I. F. & Hanson, K. P. Amplification of ERBB-2 (HER-2/NEU) oncogene in different neoplasms of patients from USSR. Oncology 49, 162–165 (1992).
  CAS PubMed Google Scholar
• Fajac, A. et al. c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis. Int. J. Cancer 64, 146–151 (1995).
  CAS PubMed Google Scholar
• Fan, Q. B. et al. Amplification of the C-erbB-2(HER-2/neu) proto-oncogene in ovarian carcinomas. Chin. Med. J. (Engl) 107, 589–593 (1994).
  CAS Google Scholar
• Hou, Y., Wang, M. & Liu, W. Study of the amplification and expression of c-erbB2 oncogene in epithelial ovarian tumors. Zhonghua Zhong Liu Za Zhi 18, 426–428 (1996).
  CAS PubMed Google Scholar
• Anreder, M. B., Freeman, S. M., Merogi, A., Halabi, S. & Marrogi, A. J. p53, c-erbB2, and PCNA status in benign, proliferative and malignant ovarian surface epithelial neoplasms: a study of 75 cases. Arch. Pathol. Lab. Med. 123, 310–316 (1999).
  CAS PubMed Google Scholar
• Berchuck, A. et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50, 4087–4091 (1990).
  CAS PubMed Google Scholar
• Huettner, P. C. et al. Neu oncogene expression in ovarian tumors: a quantitative study. Mod. Pathol. 5, 250–256 (1992).
  CAS PubMed Google Scholar
• Yazici, H., Dolapcioglu, K., Buyru, F. & Dalay, N. Utility of c-erbB-2 expression in tissue and sera of ovarian cancer patients. Cancer Invest. 18, 110–114 (2000).
  CAS PubMed Google Scholar
• Haldane, J. S., Hird, V., Hughes, C. M. & Gullick, W. J. c-erbB-2 oncogene expression in ovarian cancer. J. Pathol. 162, 231–237 (1990).
  CAS PubMed Google Scholar
• Wang, D. P. et al. Immunohistochemical localization of c-erbB-2 protein and epidermal growth factor receptor in normal surface epithelium, surface inclusion cysts, and common epithelial tumours of the ovary. Virchows Arch. A Pathol. Anat. Histopathol. 421, 393–400 (1992).
  CAS PubMed Google Scholar
• Ross, J. S. et al. HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary. Am. J. Clin. Pathol. 111, 311–316 (1999).
  CAS PubMed Google Scholar
• Wang, Y. P., Chen, S. Q. & Xue, K. X. Amplification of C-erB-2 oncogene in colon carcinomas. Zhonghua Yi Xue Za Zhi 74, 536–538, 582 (1994).
  CAS PubMed Google Scholar
• Nathanson, D. R. et al. HER 2/neu expression and gene amplification in colon cancer. Int. J. Cancer 105, 796–802 (2003).
  CAS PubMed Google Scholar
• McKay, J. A. et al. c-erbB-2 is not a major factor in the development of colorectal cancer. Br. J. Cancer 86, 568–573 (2002).
  CAS PubMed PubMed Central Google Scholar
• Dursun, A., Poyraz, A., Suer, O., Sezer, C. & Akyol, G. Expression of Bcl-2 and c-ErbB-2 in colorectal neoplasia. Pathol. Oncol. Res. 7, 24–27 (2001).
  CAS PubMed Google Scholar
• Ross, J. S. & McKenna, B. J. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest. 19, 554–568 (2001).
  CAS PubMed Google Scholar
• Esteller, M., Garcia, A., Martinez i Palones, J. M., Cabero, A. & Reventos, J. Detection of c-erbB-2/neu and fibroblast growth factor-3/INT-2 but not epidermal growth factor receptor gene amplification in endometrial cancer by differential polymerase chain reaction. Cancer 75, 2139–2146 (1995).
  CAS PubMed Google Scholar
• Czerwenka, K., Lu, Y. & Heuss, F. Amplification and expression of the c-erbB-2 oncogene in normal, hyperplastic, and malignant endometria. Int. J. Gynecol. Pathol. 14, 98–106 (1995).
  CAS PubMed Google Scholar
• Halperin, R. et al. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur. J. Gynaecol. Oncol. 22, 122–126 (2001).
  CAS PubMed Google Scholar
• Ioffe, O. B., Papadimitriou, J. C. & Drachenberg, C. B. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium. Hum. Pathol. 29, 1150–1159 (1998).
  CAS PubMed Google Scholar
• Miyazaki, M. Immunohistochemical study of PCNA, p53 gene product and c-erbB-2 gene product in endometrial carcinoma. Nippon Sanka Fujinka Gakkai Zasshi 48, 269–276 (1996).
  CAS PubMed Google Scholar
• Rolitsky, C. D., Theil, K. S., McGaughy, V. R., Copeland, L. J. & Niemann, T. H. HER-2/neu amplification and overexpression in endometrial carcinoma. Int. J. Gynecol. Pathol. 18, 138–143 (1999).
  CAS PubMed Google Scholar
• Wang, D. et al. Expression of c-erbB-2 protein and epidermal growth receptor in endometrial carcinomas. Correlation with clinicopathologic and sex steroid receptor status. Cancer 72, 2628–2637 (1993).
  CAS PubMed Google Scholar
• Pinto-de-Sousa, J. et al. c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int. J. Surg. Pathol. 10, 247–256 (2002).
  CAS PubMed Google Scholar
• Kameda, T. et al. Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. Cancer Res. 50, 8002–8009 (1990).
  CAS PubMed Google Scholar
• Ranzani, G. N. et al. Heterogeneous protooncogene amplification correlates with tumor progression and presence of metastases in gastric cancer patients. Cancer Res. 50, 7811–7814 (1990).
  CAS PubMed Google Scholar
• Tsujino, T. et al. Alterations of oncogenes in metastatic tumours of human gastric carcinomas. Br. J. Cancer 62, 226–230 (1990).
  CAS PubMed PubMed Central Google Scholar
• Lee, K. E. et al. Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J. Clin. Oncol. 33, 173–179 (2003).
  PubMed Google Scholar
• Wang, Y. L., Sheu, B. S., Yang, H. B., Lin, P. W. & Chang, Y. C. Overexpression of c-erb-B2 proteins in tumor and non-tumor parts of gastric adenocarcinoma — emphasis on its relation to H. pylori infection and clinicohistological characteristics. Hepatogastroenterology 49, 1172–1176 (2002).
  CAS PubMed Google Scholar
• Takehana, T. et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int. J. Cancer 98, 833–837 (2002).
  CAS PubMed Google Scholar
• Suzuki, T. et al. Growth of human gastric carcinomas and expression of epidermal growth factor, transforming growth factor-α, epidermal growth factor receptor and p185c-erbB-2. Oncology 52, 385–391 (1995).
  CAS PubMed Google Scholar
• Yan, J. et al. Absence of evidence for HER2 amplification in nasopharyngeal carcinoma. Cancer Genet. Cytogenet. 132, 116–119 (2002).
  CAS PubMed Google Scholar
• Khan, A. J. et al. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin. Cancer Res. 8, 540–548 (2002).
  CAS PubMed Google Scholar
• Leonard, J. H., Kearsley, J. H., Chenevix-Trench, G. & Hayward, N. K. Analysis of gene amplification in head-and-neck squamous-cell carcinoma. Int. J. Cancer 48, 511–515 (1991).
  CAS PubMed Google Scholar
• Merritt, W. D., Weissler, M. C., Turk, B. F. & Gilmer, T. M. Oncogene amplification in squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 116, 1394–1398 (1990).
  CAS PubMed Google Scholar
• Beckhardt, R. N. et al. HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 121, 1265–1270 (1995).
  CAS PubMed Google Scholar
• Yazici, H., Altun, M., Alatli, C., Dogan, O. & Dalay, N. c-erbB-2 gene amplification in nasopharyngeal carcinoma. Cancer Invest. 18, 6–10 (2000).
  CAS PubMed Google Scholar
• Cho, K. J., Khang, S. K., Koh, J. S., Chung, J. H. & Lee, S. S. Sebaceous carcinoma of the eyelids: frequent expression of c-erbB-2 oncoprotein. J. Korean Med. Sci. 15, 545–550 (2000).
  CAS PubMed PubMed Central Google Scholar
• Shnayder, Y. et al. Adhesion molecules as prognostic factors in nasopharyngeal carcinoma. Laryngoscope 111, 1842–1846 (2001).
  CAS PubMed Google Scholar
• Skalova, A., Starek, Kucerova, V., Szepe, P. & Plank, L. Salivary duct carcinoma — a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. Pathol. Res. Pract. 197, 621–626 (2001).
  CAS PubMed Google Scholar
• Shiraishi, M., Noguchi, M., Shimosato, Y. & Sekiya, T. Amplification of protooncogenes in surgical specimens of human lung carcinomas. Cancer Res. 49, 6474–6479 (1989).
  CAS PubMed Google Scholar
• Bongiorno, P. F. et al. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas. J. Thorac. Cardiovasc. Surg. 107, 590–595 (1994).
  CAS PubMed Google Scholar
• Han, H. et al. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer. Hum. Pathol. 33, 105–110 (2002).
  CAS PubMed Google Scholar
• Nakamura, H. et al. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer. Int. J. Cancer 103, 61–66 (2003).
  CAS PubMed Google Scholar
• Hirsch, F. R. et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br. J. Cancer 86, 1449–1456 (2002).
  CAS PubMed PubMed Central Google Scholar
• Hirashima, N., Takahashi, W., Yoshii, S., Yamane, T. & Ooi, A. Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immuno-histochemical and fluorescence in situ hybridization study. Mod. Pathol. 14, 556–562 (2001).
  CAS PubMed Google Scholar
• Cox, G. et al. Herceptest: HER2 expression and gene amplification in non-small cell lung cancer. Int. J. Cancer 92, 480–483 (2001).
  CAS PubMed Google Scholar
• Reinmuth, N. et al. Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. Eur. Respir. J. 16, 991–996 (2000).
  CAS PubMed Google Scholar
• Brabender, J. et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin. Cancer Res. 7, 1850–1855 (2001).
  CAS PubMed Google Scholar
• Schneider, P. M. et al. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br. J. Cancer 83, 473–479 (2000).
  CAS PubMed PubMed Central Google Scholar
• Fournier, G. et al. Gene amplifications in advanced-stage human prostate cancer. Urol. Res. 22, 343–347 (1995).
  CAS PubMed Google Scholar
• Latil, A. et al. Oncogene amplifications in early-stage human prostate carcinomas. Int. J. Cancer 59, 637–638 (1994).
  CAS PubMed Google Scholar
• Ross, J. S. et al. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. Hum. Pathol. 28, 827–833 (1997).
  CAS PubMed Google Scholar
• Sanchez, K. M. et al. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a request for a standardized, organ specific methodology. Cancer 95, 1650–1655 (2002).
  PubMed Google Scholar
• Lara, P. N. et al. HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial. Cancer 94, 2584–2589 (2002).
  PubMed Google Scholar
• Savinainen, K. J. et al. Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am. J. Pathol. 160, 339–345 (2002).
  CAS PubMed PubMed Central Google Scholar
• Liu, H. L., Gandour-Edwards, R., Lara, P. N., Jr., de Vere White, R. & LaSalle, J. M. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization. Cancer J. 7, 395–403 (2001).
  CAS PubMed Google Scholar
• Osman, I. et al. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin. Cancer Res. 7, 2643–2647 (2001).
  CAS PubMed Google Scholar
• Gu, K., Mes-Masson, A. M., Gauthier, J. & Saad, F. Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. Cancer Lett. 99, 185–189 (1996).
  CAS PubMed Google Scholar
• Shi, Y. et al. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J. Urol. 166, 1514–1519 (2001).
  CAS PubMed Google Scholar
• McCann, A., Dervan, P. A., Johnston, P. A., Gullick, W. J. & Carney, D. N. c-erbB-2 oncoprotein expression in primary human tumors. Cancer 65, 88–92 (1990).
  CAS PubMed Google Scholar
• Kruger, S. et al. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int. J. Oncol. 21, 981–987 (2002).
  PubMed Google Scholar
• Mellon, J. K. et al. C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J. Urol. 155, 321–326 (1996).
  CAS PubMed Google Scholar
• Sauter, G. et al. DNA aberrations in urinary bladder cancer detected by flow cytometry and FISH. Urol. Res. 25, S37–S44 (1997).
  CAS PubMed Google Scholar
• Gorgoulis, V. G., Barbatis, C., Poulias, I. & Karameris, A. M. Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients. Mod. Pathol. 8, 758–764 (1995).
  CAS PubMed Google Scholar
• Orlando, C. et al. Detection of c-erbB-2 amplification in transitional cell bladder carcinoma using competitive PCR technique. J. Urol. 156, 2089–2093 (1996).
  CAS PubMed Google Scholar
• Simon, R. et al. HER-2 and TOP2A co-amplification in urinary bladder cancer. Int. J. Cancer 107, 764–772 (2003).
  CAS PubMed Google Scholar
• Zhau, H. E. et al. Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. Mol. Carcinog. 3, 254–257 (1990).
  CAS PubMed Google Scholar